Otherwise, lipid metabolism, represented by the de novo fatty acid (FA)-related pathway, has been confirmed to be required for RCC, targeting associated biomarkers, like fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and carnitine palmitoyltransferase 1A (CPT1A), which have been proposed to be potential clinical strategies (25). This evidence concerns the gene SCD and renal cell carcinoma.